Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
6.69
+0.50 (8.08%)
At close: Feb 6, 2026, 4:00 PM EST
6.68
-0.01 (-0.15%)
After-hours: Feb 6, 2026, 7:05 PM EST
Unicycive Therapeutics Employees
As of December 31, 2024, Unicycive Therapeutics had 23 total employees, including 22 full-time and 1 part-time employees. The number of employees increased by 9 or 64.29% compared to the previous year.
Employees
23
Change (1Y)
9
Growth (1Y)
64.29%
Revenue / Employee
n/a
Profits / Employee
-$1,452,696
Market Cap
143.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 23 | 9 | 64.29% | 22 | 1 |
| Dec 31, 2023 | 14 | 2 | 16.67% | 14 | 0 |
| Dec 31, 2022 | 12 | 3 | 33.33% | 12 | 0 |
| Dec 31, 2021 | 9 | 8 | 800.00% | 9 | 0 |
| Dec 31, 2020 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Caribou Biosciences | 147 |
| Rani Therapeutics Holdings | 106 |
| Nkarta | 105 |
| Vaxart | 105 |
| Acumen Pharmaceuticals | 61 |
| Elicio Therapeutics | 32 |
| Spero Therapeutics | 32 |
UNCY News
- 4 days ago - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit - GlobeNewsWire
- 9 days ago - Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
- 10 days ago - UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 10 days ago - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 5 weeks ago - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - GlobeNewsWire
- 2 months ago - Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp
- 2 months ago - Unicycive Therapeutics to Participate in Upcoming Investor Events in December - GlobeNewsWire
- 3 months ago - Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire